Loading...
XSHG
600866
Market cap1.11bUSD
Jul 10, Last price  
4.60CNY
1D
1.55%
1Q
-34.00%
Jan 2017
-35.03%
Name

Star Lake Bioscience Co Inc Zhaoqing Guangdong

Chart & Performance

D1W1MN
XSHG:600866 chart
P/E
7.81
P/S
0.48
EPS
0.59
Div Yield, %
8.39%
Shrs. gr., 5y
17.58%
Rev. gr., 5y
70.11%
Revenues
15.90b
-8.27%
768,413,369768,807,889982,171,0581,366,052,2471,376,879,9271,063,088,4061,091,200,516902,804,492871,491,716729,761,469679,847,503686,969,427859,110,0321,049,609,5311,116,277,2684,071,248,58517,486,316,70317,373,727,88317,334,410,10915,900,091,829
Net income
979m
+3.79%
19,179,045-138,559,33929,000,889224,520,604284,993,43987,685,906-202,848,84820,235,138-360,800,569-422,354,41324,306,190-158,273,18842,280,337149,552,374148,710,270152,139,248608,326,065677,954,278943,152,843978,889,506
CFO
1.29b
-46.12%
35,144,37382,277,757148,934,446316,728,554104,629,83865,883,9380002,745,29141,169,38540,050,03450,686,252213,169,117249,985,729192,629,0971,662,506,5692,026,097,9662,397,755,6951,292,006,735
Dividend
Jun 23, 20250.38 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1964 and headquartered in Zhaoqing, China, Star Lake Bioscience Co., Inc. specializes in the production and global distribution of pharmaceutical ingredients, as well as food and animal feed additives. Its extensive product catalog includes guanosine, which serves as a crucial intermediate for both food and pharmaceutical applications. The company also manufactures L-proline, a vital intermediate for synthesizing captopril and enalapril, and a raw material used in amino acid transfusions. Another key offering is Adefovir dipivoxil tablets, formulated to combat Hepatitis B by inhibiting HBV DNA polymerase activity and disrupting the virus's DNA. Additionally, L-threonine is provided for its application in animal feed premixes, particularly for pigs and poultry. Star Lake Bioscience further supplies disodium 5'-ribonucleotide, utilized in the treatment of chronic hepatitis, muscular atrophy, and certain eye conditions. Similarly, disodium 5-inosinate addresses issues like leukopenia, thrombocytopenia, and both acute and chronic hepatitis. Inosine is another significant product, prescribed for various ailments including chronic hepatitis, heart disease, low white blood cell or platelet counts, and central choroidoretinitis. Furthermore, disodium 5'-guanylate finds application in food preservation, such as for canned meats, ham, and other salted meat products. The company's broad portfolio also features compounds such as ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, and L-lysine, among others. These diverse offerings are marketed under the proprietary brands Star Lake and Yue Bao.
IPO date
Aug 18, 1994
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT